Format

Send to

Choose Destination
Am J Psychiatry. 2016 Dec 1;173(12):1239-1241.

Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept.

Author information

1
From the Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, Calif.; the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif.; the Department of Psychology, The Hebrew University of Jerusalem, Israel; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York; the New York State Psychiatric Institute, New York; Aptinyx, Evanston, Ill.; and the Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, McCormick School of Engineering and Applied Sciences, Northwestern University, Evanston, Ill.

KEYWORDS:

AMPA; Clinical Drug Studies; GLYX-13; Ketamine; NMDA; OCD; Obsessive-Compulsive Disorder; Rapastinel

PMID:
27903098
PMCID:
PMC5304999
DOI:
10.1176/appi.ajp.2016.16080868
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center